In a report released today, Devin Ryan from JMP Securities maintained a Buy rating on Owl Rock Capital (ORCC – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $13.14.
Ryan covers the Financial sector, focusing on stocks such as Cowen Group, Raymond James Financial, and Houlihan Lokey. According to TipRanks, Ryan has an average return of 14.9% and a 60.90% success rate on recommended stocks.
In addition to JMP Securities, Owl Rock Capital also received a Buy from Raymond James’s Robert Dodd in a report issued on August 5. However, on July 25, Wells Fargo downgraded Owl Rock Capital (NYSE: ORCC) to a Sell.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $15.33 and a one-year low of $12.09. Currently, Owl Rock Capital has an average volume of 2.32M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Owl Rock Capital Corp, non traded business development company, seeks investment opportunities in middle market companies located in the US with an EBITDA of $10 to $250 million and annual revenue of $50 million to $2.5 billion. It focuses on broad range of sectors including business services, healthcare services, pharma & healthcare technology, aerospace & defences, software & technology and manufacturing & industrials. The fund provides financing in the form of senior secured or unsecured loans, subordinated loans or mezzanine loans and a lesser extent, equity-related securities and warrants for growth, acquisitions, market or product expansion, re-financings and recapitalizations. Its investment size ranging from $20 to $250 million and it also acts as a lead investor.
Read More on ORCC:
- Century Casinos (CNTY) Receives a Buy from JMP Securities
- Western Digital Stock: Current Headwinds Present an Attractive Opportunity
- JMP Securities Remains a Buy on Compugen (CGEN)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Cellectis SA (CLLS) and Orthofix (OFIX)
- JMP Securities Sticks to Its Hold Rating for NextCure (NXTC)
